Guidelines for Palliative Treatment of Spinal Metastases: Choosing Between Stereotactic Body Radiation Therapy and Conventional Fractionation

Eckstein, Jacob; Koffler, Daniel; Parashar, Bhupesh; Potters, Louis; Narayana, Ashwatha

doi:10.46883/onc.2021.3502.0063

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…• If surgery is not indicated, palliative stereotactic body radiotherapy of 16-24 Gy in 1 fraction or 24-30 Gy in 3 fractions is administered (Eckstein 2021 52 ).…”

Section: Malignant Spinal Cord Compression (Continued)mentioning

confidence: 99%

See 1 more Smart Citation

Oncologic emergencies and urgencies: A comprehensive review

Rothberg

Quest

Yeung

et al. 2022

CA A Cancer J Clinicians

View full text Add to dashboard Cite

Patients with advanced cancer generate 4 million visits annually to emergency departments (EDs) and other dedicated, high‐acuity oncology urgent care centers. Because of both the increasing complexity of systemic treatments overall and the higher rates of active therapy in the geriatric population, many patients experiencing acute decompensations are frail and acutely ill. This article comprehensively reviews the spectrum of oncologic emergencies and urgencies typically encountered in acute care settings. Presentation, underlying etiology, and up‐to‐date clinical pathways are discussed. Criteria for either a safe discharge to home or a transition of care to the inpatient oncology hospitalist team are emphasized. This review extends beyond familiar conditions such as febrile neutropenia, hypercalcemia, tumor lysis syndrome, malignant spinal cord compression, mechanical bowel obstruction, and breakthrough pain crises to include a broader spectrum of topics encompassing the syndrome of inappropriate antidiuretic hormone secretion, venous thromboembolism and malignant effusions, as well as chemotherapy‐induced mucositis, cardiomyopathy, nausea, vomiting, and diarrhea. Emergent and urgent complications associated with targeted therapeutics, including small molecules, naked and drug‐conjugated monoclonal antibodies, as well as immune checkpoint inhibitors and chimeric antigen receptor T‐cells, are summarized. Finally, strategies for facilitating same‐day direct admission to hospice from the ED are discussed. This article not only can serve as a point‐of‐care reference for the ED physician but also can assist outpatient oncologists as well as inpatient hospitalists in coordinating care around the ED visit.

show abstract

“…• If surgery is not indicated, palliative stereotactic body radiotherapy of 16-24 Gy in 1 fraction or 24-30 Gy in 3 fractions is administered (Eckstein 2021 52 ).…”

Section: Malignant Spinal Cord Compression (Continued)mentioning

confidence: 99%

“…Although these complications can be the initial presenting symptom, many occur in the setting of progression of disease or as a consequence of treatment (Table 3). 42‐69 …”

Section: Cancer‐related Structural Complicationsmentioning

confidence: 99%

Oncologic emergencies and urgencies: A comprehensive review

Rothberg

Quest

Yeung

et al. 2022

CA A Cancer J Clinicians

View full text Add to dashboard Cite

show abstract

“…The treatment method for patients with metastatic spine tumors is determined according to patient status, location and extent of metastasis, neurologic status, and spinal stability. 3,4 Surgical treatment is performed to improve quality of life by prolonging overall survival, improving gait, and maintaining bowel and bladder function through nerve decompression and spinal stabilization. 5 In addition, radiotherapy is also performed in many patients.…”

Section: Introductionmentioning

confidence: 99%

Risk factors for 90-day readmission in metastatic spine tumors in South Korea: A nationwide population-based study from 2012 to 2019

Cho

Noh

Kim

et al. 2023

Preprint

View full text Add to dashboard Cite

Population-based studies on the cause of readmission within 90 days after surgery or radiotherapy for metastatic spine tumors are scarce. We aimed to investigate the risk factors for readmission within 90 days after initial surgical or radiation treatment for metastatic spine tumors. Patients who were diagnosed with metastatic spine tumors between 2012 and 2019 and who underwent spinal magnetic resonance imaging within 1 year were classified according to treatment (surgical or radiotherapy), and the causes for the 90-day readmission and patient characteristics were compared. Overall, 15,815 patients (surgical group, 13,974 patients; radiotherapy group, 1,841 patients) were evaluated. Radiotherapy was preferred in younger and male patients with high Charlson comorbidity index (CCI). Meanwhile, surgery was mainly performed in patients with lumbar metastasis. Radiotherapy, age 30–69 years, male sex, and CCI > 1 were risk factors for 90-day readmission. The main cause of 90-day readmissions included tumor recurrence, chemotherapy, radiotherapy, and treatment of other organ metastasis with radiotherapy. Patients with lung, breast, liver, and colorectal origin and treated with radiotherapy had a high 90-day readmission rate. Radiotherapy, age 30–69 years, male sex, and CCI > 1 increase the risk for 90-day readmission in patients with metastatic spine tumors.

show abstract

Exploring the Use of Contour-Based Intrafraction Motion Review for Spine Stereotactic Body Radiation Therapy Treatments

Jank,

Cetnar

2024

Advances in Radiation Oncology

View full text Add to dashboard Cite

Guidelines for Palliative Treatment of Spinal Metastases: Choosing Between Stereotactic Body Radiation Therapy and Conventional Fractionation

Cited by 5 publications

References 0 publications

Oncologic emergencies and urgencies: A comprehensive review

Oncologic emergencies and urgencies: A comprehensive review

Risk factors for 90-day readmission in metastatic spine tumors in South Korea: A nationwide population-based study from 2012 to 2019

Exploring the Use of Contour-Based Intrafraction Motion Review for Spine Stereotactic Body Radiation Therapy Treatments

Contact Info

Product

Resources

About